市場調査レポート

商品コード

1403359

骨髄増殖性疾患市場の2030年までの予測：タイプ別、診断とスクリーニング方法別、治療オプション別、エンドユーザー別、地域別の世界分析

Myeloproliferative Disorders Market Forecasts to 2030 - Global Analysis By Type, Diagnosis and Screening Methods, Treatment Option, End User and By Geography

出版日: 2024年01月01日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 650,554円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 822,990円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 995,426円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,175,700円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の骨髄増殖性疾患市場は予測期間中CAGR 4.4％で成長しています。

骨髄増殖性疾患（MPD）として知られる珍しい血液疾患の一群は、骨髄の成熟した血液細胞の過剰生産によって定義されます。赤血球、白血球、血小板は、この異常増殖の影響を受ける細胞のひとつです。定期的なモニタリングは、疾患の管理および急性白血病への潜在的な進行を予防するために極めて重要です。管理の目標は、症状を最小限に抑え、合併症を減らし、症状の悪化を食い止めることです。

国際がん研究機関が提供した2021年のデータによると、2020年の欧州地域のがん患者数は479万人で、2040年には607万人に増加すると予測されています。

疾患啓発における需要の高まり

骨髄増殖性疾患（MPD）は、一般市民や医療従事者の間で、これらの疾患に対する認知度が向上することで発見されます。教育、ヘルスケアへの取り組み、アドボカシーのためのキャンペーンは、認知を広めるために不可欠であり、それに対応して革新的な治療法や療法に対する需要も増加しています。このように、病気に対する認知度の向上は、早期介入を促し、罹患者の標準治療を向上させることで、MPDにプラスの影響を与え、市場規模を押し上げています。

高額な治療費

政府や保険会社は、骨髄増殖性疾患（MPD）に対する広範で高額な治療を提供することによる財政的負担を処理することが困難であると考えるかもしれないです。患者や医療制度は、薬物療法、治療、幹細胞移植の可能性などにかかる高額な費用のために財政的負担を負い、全体的な健康状態に影響を及ぼす可能性があります。したがって、治療費の高騰は骨髄増殖性障害（MPD）市場における大きな抑制要因となっています。

診断技術の進歩

分子プロファイリング、画像診断、遺伝子検査における新たな開発は、MPD診断の精度と有効性を向上させています。また、診断技術の向上により、迅速な介入が容易になり、病気の経過やその影響を遅らせることができます。さらに、診断技術の継続的な研究開発は、骨髄増殖性疾患の診断を最適化し、医療従事者が十分な情報を得た上で意思決定できるよう支援することに専念していることを示し、その結果、市場の拡大を徐々に後押ししています。

医薬品開発における遺伝的複雑性

薬剤開発の努力は、MPDの遺伝的スペクトル全体に適用可能な共通の分子標的を同定する上で障害に直面しています。JAK2遺伝子、CALR遺伝子、MPL遺伝子の変異など、サブタイプごとに異なるアプローチが必要とされ、疾患表現型が異なるためです。加えて、根治的な治療法の開発や、複雑な分子メカニズムに対する現在進行中の研究は減少しており、そのことが疾患セグメントの拡大を妨げています。

COVID-19の影響

パンデミックは日常的なヘルスケアサービスを混乱させ、真性多血症、本態性血小板血症、骨髄線維症などの疾患を含む多くのMPD患者の診断や治療開始の遅れにつながっており、免疫系の低下や感染症への感受性の増加によりリスクが高まっています。したがって、骨髄増殖性疾患市場は、これらの複合的な要因の結果として困難に直面し、患者の治療や市場拡大全体に影響を及ぼしています。

予測期間中、真性多血症（PV）分野が最大となる見込み

真性多血症（PV）分野が最大のシェアを占めると推定されます。PVは骨髄の障害を特徴とし、血液の高粘度化、凝固、心血管障害を引き起こす可能性があります。現在進行中の研究の目標は、PV患者の生活を改善し、症状を管理し、血栓症のリスクを低下させる新規治療法を生み出すことです。このように、骨髄増殖性疾患市場は、疾患のコントロールと患者の全体的な健康状態の改善との微妙なバランスが特徴であり、これがこの分野の拡大を牽引しています。

骨髄生検セグメントは予測期間中最も高いCAGRが見込まれる

骨髄生検分野は予測期間中に最も高いCAGRが見込まれます。骨髄生検は、細胞産生の異常を判定し、骨髄の健康状態を評価するために不可欠な診断プロセスです。遺伝子変異、細胞形態、骨髄増殖性疾患の経過を知る上で極めて重要です。加えて、研究者は生検方法を改善し、分子的洞察をより活用するための実験を行っています。これは診断の有用性を高め、これらの疾患に対するより良い治療計画の開発に役立ち、このセグメントの成長を後押ししています。

最大のシェアを占める地域

アジア太平洋地域は、政府およびヘルスケア機関が協力して意識を高め、診断技術を向上させ、最先端の治療法へのアクセスを保証しているため、予測期間中に最大の市場シェアを占めました。中国、日本、インドを含むこの地域の主要企業や主要諸国では、MPDの革新的治療に焦点を当てた研究開発活動が急増しています。そのため、標的治療や幹細胞移植などの先進的な治療法の導入が進み、この地域の成長をさらに後押ししています。

CAGRが最も高い地域：

北米は、分子検査や遺伝子プロファイリングのような、正確な疾患の特定を可能にする洗練された診断ツールにより、予測期間中に最も高いCAGRを示すと予想されます。こうしたビッグデータ解析や人工知能の発達は、MPDのより包括的な知識とカスタマイズされた治療戦略を支えています。さらに、副作用を最小限に抑えながら治療効果を高めるヤヌスキナーゼ（JAK）阻害剤などの標的療法に注目が集まっており、これがこの地域の拡大を後押ししています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Novartis AG
Teva Pharmaceutical Industries
AbbVie
Bristol Myers Squibb（BMS）
Roche
Incyte Corporation
Gilead Sciences
MP Biomedicals
Mylan
Roxall Medizin
AOP Orphan Pharmaceuticals AG
CTI BioPharma Corp
Promedior, Inc.
Celgene

図表

List of Tables

Table 1 Global Myeloproliferative Disorders Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 4 Global Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
Table 5 Global Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
Table 6 Global Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
Table 7 Global Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
Table 8 Global Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
Table 9 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
Table 10 Global Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
Table 11 Global Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
Table 12 Global Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
Table 13 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
Table 14 Global Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
Table 15 Global Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
Table 16 Global Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
Table 17 Global Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 18 Global Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
Table 19 Global Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
Table 20 Global Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 21 Global Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
Table 22 Global Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 23 Global Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 24 North America Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 25 North America Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 26 North America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 27 North America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
Table 28 North America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
Table 29 North America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
Table 30 North America Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
Table 31 North America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
Table 32 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
Table 33 North America Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
Table 34 North America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
Table 35 North America Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
Table 36 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
Table 37 North America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
Table 38 North America Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
Table 39 North America Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
Table 40 North America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 41 North America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
Table 42 North America Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
Table 43 North America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 44 North America Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
Table 45 North America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 46 North America Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 47 Europe Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 48 Europe Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 49 Europe Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 50 Europe Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
Table 51 Europe Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
Table 52 Europe Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
Table 53 Europe Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
Table 54 Europe Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
Table 55 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
Table 56 Europe Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
Table 57 Europe Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
Table 58 Europe Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
Table 59 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
Table 60 Europe Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
Table 61 Europe Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
Table 62 Europe Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
Table 63 Europe Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 64 Europe Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
Table 65 Europe Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
Table 66 Europe Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 67 Europe Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
Table 68 Europe Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 69 Europe Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 70 Asia Pacific Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 71 Asia Pacific Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 72 Asia Pacific Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 73 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
Table 74 Asia Pacific Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
Table 75 Asia Pacific Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
Table 76 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
Table 77 Asia Pacific Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
Table 78 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
Table 79 Asia Pacific Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
Table 80 Asia Pacific Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
Table 81 Asia Pacific Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
Table 82 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
Table 83 Asia Pacific Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
Table 84 Asia Pacific Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
Table 85 Asia Pacific Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
Table 86 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 87 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
Table 88 Asia Pacific Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
Table 89 Asia Pacific Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 90 Asia Pacific Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
Table 91 Asia Pacific Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 92 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 93 South America Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 94 South America Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 95 South America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 96 South America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
Table 97 South America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
Table 98 South America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
Table 99 South America Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
Table 100 South America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
Table 101 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
Table 102 South America Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
Table 103 South America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
Table 104 South America Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
Table 105 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
Table 106 South America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
Table 107 South America Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
Table 108 South America Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
Table 109 South America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 110 South America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
Table 111 South America Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
Table 112 South America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 113 South America Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
Table 114 South America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 115 South America Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
Table 116 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
Table 117 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
Table 118 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 119 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
Table 120 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
Table 121 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
Table 122 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
Table 123 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
Table 124 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
Table 125 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
Table 126 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
Table 127 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
Table 128 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
Table 129 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
Table 130 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
Table 131 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
Table 132 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 133 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
Table 134 Middle East & Africa Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
Table 135 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 136 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
Table 137 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
Table 138 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24584

According to Stratistics MRC, the Global Myeloproliferative Disorders Market is growing at a CAGR of 4.4% during the forecast period. A class of uncommon blood diseases known as myeloproliferative disorders (MPDs) is defined by the bone marrow's overproduction of mature blood cells. Red blood cells, white blood cells, and platelets are among the cells that are impacted by this aberrant proliferation. Regular monitoring is crucial for disease management and to prevent potential progression to acute leukemia. The goals of management are to minimize symptoms, cut down on complications, and stop the condition from getting worse.

According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Market Dynamics:

Driver:

Rising demand in disease awareness

Myeloproliferative Disorders (MPDs) among the general public and healthcare professionals are detected by improving recognition of these conditions. Campaigns for education, healthcare initiatives, and advocacy are essential in spreading awareness and there is a corresponding increase in demand for innovative treatments and therapies. Thus, all things considered, increased awareness of the disease has a positive impact on the MPD by encouraging early intervention and enhancing the standard of care for those who are affected which is driving the market size.

Restraint:

High cost treatment

Governments and insurance companies might find it difficult to handle the financial strain of offering extensive and expensive treatments for myeloproliferative disorder (MPD). Patients and healthcare systems bear a financial burden due to the high costs of medications, therapies, and possible stem cell transplants potentially impacting their overall health outcomes. Therefore, the high cost of treatment serves as a significant restraint in the myeloproliferative disorder (MPD) market.

Opportunity:

Technological advancements in diagnosis

New developments in molecular profiling, imaging, and genetic testing improve the precision and efficacy of MPD diagnosis. Improved diagnostic skills also make it easier to intervene quickly, which slows the course of the illness and its consequences. In addition, continuous research and development in diagnostic technologies demonstrates a dedication in optimizing the diagnosis of myeloproliferative disorders, assisting medical professionals in making well-informed decisions, and therefore gradually driving market expansion.

Threat:

Genetic complexities in drug development

Drug development efforts face obstacles in identifying common molecular targets applicable across the genetic spectrum of MPDs. This complexity makes it challenging to develop universal targeted therapies, as each subtype may require a distinct approach including mutations in JAK2, CALR, and MPL genes, leading to varied disease phenotypes. In addition, the development of curative therapies and ongoing research to intricate molecular mechanisms are decreased thereby hampering the segment expansion.

COVID-19 Impact

The pandemic has disrupted routine healthcare services, leading to delayed diagnoses and treatment initiation for many MPD patients, including conditions like polycythemia vera, essential thrombocythemia, and myelofibrosis, face heightened risks due to compromised immune systems and increased susceptibility to infections. Therefore, the market for myeloproliferative disorders faced difficulties as a result of these combined factors, which have an impact on patient care and market expansion overall.

The polycythemia vera (PV) segment is expected to be the largest during the forecast period

The Polycythemia Vera (PV) segment is estimated to hold the largest share. PV is characterized by a disorder of the bone marrow that can cause high blood viscosity, clotting, and cardiovascular problems. The goal of ongoing research is to create novel therapies that will help PV patients live better, manage their symptoms, and lower their risk of thrombosis. Thus, the myeloproliferative disorders market is characterized by a delicate balance between disease control and improving patients' overall well-being which is driving this segment expansion.

The bone marrow biopsy segment is expected to have the highest CAGR during the forecast period

The bone marrow biopsy segment is anticipated to have highest CAGR during the forecast period. It is a diagnostic process that is essential for determining abnormalities in cell production and evaluating the health of the bone marrow. They are crucial for learning about genetic mutations, cell morphology, and the course of myeloproliferative disorders. In addition, researchers are conducting experiments to improve biopsy methods and make better use of molecular insights, which will increase their diagnostic utility and help in developing better treatment plans for these conditions which are boosting this segment growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to governments and healthcare organizations which work together in raising awareness, advance diagnostic skills, and guarantee access to cutting-edge treatments. Key players and key countries in the region, including China, Japan, and India, have witnessed a surge in research and development activities focused on innovative therapies for MPDs. Therefore, this has resulted in introducing advanced treatment options, including targeted therapies and stem cell transplantation which further propel the growth of the region.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to sophisticated diagnostic tools that allow for accurate disease identification, like molecular testing and genetic profiling. These developments in big data analytics and artificial intelligence support more comprehensive knowledge of MPDs and customized treatment strategies. Moreover, people are turning to targeted therapies, such as Janus kinase (JAK) inhibitors, which increase treatment efficacy while minimizing side effects, which are driving the region's expansion.

Key players in the market:

Some of the key players in the Myeloproliferative Disorders Market include Novartis AG, Teva Pharmaceutical Industries, AbbVie, Bristol Myers Squibb (BMS), Roche, Incyte Corporation, Gilead Sciences, MP Biomedicals, Mylan, Roxall Medizin, AOP Orphan Pharmaceuticals AG, CTI BioPharma Corp, Promedior, Inc. and Celgene.

Key Developments:

In October 2023, Allergan Aesthetics, an AbbVie company announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines.

In September 2023, Ionis Pharmaceuticals, Inc. announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD).

In August 2023, Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.

In July 2023, DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON™) platform, announced that it has been acquired by Novartis.

Types Covered:

Polycythemia Vera
Chronic Myeloid Leukemia (CML)
Primary Myelofibrosis
Essential Thrombocythemia
Other Types

Diagnosis and Screening Methods Covered:

Bone Marrow Biopsy
Blood Tests
Genetic Testing

Treatment Options Covered:

Bone Marrow Transplant
Therapeutic Procedures
Supportive Care
Medications
Chemotherapy
Other Treatment Options

End Users Covered:

Pharmaceutical Companies
Research Institutions
Hospitals and Clinics
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Myeloproliferative Disorders Market, By Type

5.1 Introduction
5.2 Polycythemia Vera
5.3 Chronic Myeloid Leukemia (CML)
5.4 Primary Myelofibrosis
5.5 Essential Thrombocythemia
5.6 Other Types

6 Global Myeloproliferative Disorders Market, By Diagnosis and Screening Methods

6.1 Introduction
6.2 Bone Marrow Biopsy
6.3 Blood Tests
6.4 Genetic Testing

7 Global Myeloproliferative Disorders Market, By Treatment Option

7.1 Introduction
7.2 Bone Marrow Transplant
7.3 Therapeutic Procedures
7.4 Supportive Care
7.5 Medications
7.6 Chemotherapy
7.7 Other Treatment Options

8 Global Myeloproliferative Disorders Market, By End Users

8.1 Introduction
8.2 Pharmaceutical Companies
8.3 Research Institutions
8.4 Hospitals and Clinics
8.5 Other End Users

9 Global Myeloproliferative Disorders Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Novartis AG
11.2 Teva Pharmaceutical Industries
11.3 AbbVie
11.4 Bristol Myers Squibb (BMS)
11.5 Roche
11.6 Incyte Corporation
11.7 Gilead Sciences
11.8 MP Biomedicals
11.9 Mylan
11.10 Roxall Medizin
11.11 AOP Orphan Pharmaceuticals AG
11.12 CTI BioPharma Corp
11.13 Promedior, Inc.
11.14 Celgene

骨髄増殖性疾患市場の2030年までの予測：タイプ別、診断とスクリーニング方法別、治療オプション別、エンドユーザー別、地域別の世界分析

Myeloproliferative Disorders Market Forecasts to 2030 - Global Analysis By Type, Diagnosis and Screening Methods, Treatment Option, End User and By Geography

COVID-19の影響

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の骨髄増殖性疾患市場：タイプ別

第6章 世界の骨髄増殖性疾患市場：診断とスクリーニング方法別

第7章 世界の骨髄増殖性疾患市場：治療オプション別

第8章 世界の骨髄増殖性疾患市場：エンドユーザー別

第9章 世界の骨髄増殖性疾患市場：地域別

第10章 主な発展

第11章 企業プロファイル